Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 1/20 | 0.35 |
| ▸ | F10 | P00742 | 1/20 | 0.35 |
| ▸ | SMYD2 | Q9NRG4 | 2/20 | 0.33 |
| ▸ | CASP1 | P29466 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2474263 | 0.88 | SMYD2 (0.33) | SMYD2 | |
| SCHEMBL2475744 | 0.88 | SMYD2 (0.34) | F2F10SMYD2 | |
| SCHEMBL2513578 | 0.86 | F2RL3 (0.36) | F2F10SMYD2 | |
| SCHEMBL2474781 | 0.81 | SMYD2 (0.34) | SMYD2SMN1; SMN2 | |
| SCHEMBL2470851 | 0.80 | NR4A1 (0.34) | SMYD2SMN1; SMN2 | |
| SCHEMBL2474930 | 0.80 | MAPT (0.32) | F2F10SMYD2 | |
| SCHEMBL2474304 | 0.79 | CYP3A4 (0.36) | SMYD2SMN1; SMN2 | |
| SCHEMBL2476765 | 0.77 | PPARG (0.33) | SMYD2 | |
| SCHEMBL9913271 | 0.77 | F2 (0.39) | F2F10CASP1SMN1; SMN2 | |
| SCHEMBL2475752 | 0.76 | MAPT (0.38) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8846934-B2 | Substituted oxazolidinones and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-09-30 | — | — | US | disclosed |
| US-8846934-B2 | Substituted oxazolidinones and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-09-30 | — | — | US | disclosed |
| US-8846934-B2 | Substituted oxazolidinones and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-09-30 | — | — | US | disclosed |
| US-20140057951-A1 | SUBSTITUTED OXAZOLIDINONES AND THEIR USE | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-02-27 | — | — | US | disclosed |
| US-20140057951-A1 | SUBSTITUTED OXAZOLIDINONES AND THEIR USE | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-02-27 | — | — | US | disclosed |
| US-20140057951-A1 | SUBSTITUTED OXAZOLIDINONES AND THEIR USE | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-02-27 | — | — | US | disclosed |
| US-8487111-B2 | Substituted oxazolidinones and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-07-16 | — | — | US | disclosed |
| US-8487111-B2 | Substituted oxazolidinones and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-07-16 | — | — | US | disclosed |
| US-8487111-B2 | Substituted oxazolidinones and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-07-16 | — | — | US | disclosed |
| US-8383822-B2 | Substituted oxazolidinones and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-02-26 | — | — | US | disclosed |
| US-8383822-B2 | Substituted oxazolidinones and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-02-26 | — | — | US | disclosed |
| EP-2170877-B1 | SUBSTITUTED (OXAZOLIDINON-5-YL-METHYL) -2-THIOPHENE-CARBOXAMIDES AND USE THEREOF IN THE FIELD OF BLOOD COAGULATION | BAYER IP GMBH (DE) | 2012-11-21 | — | — | EP | disclosed |
| EP-2173744-B1 | SUBSTITUTED (OXAZOLIDINON-5-YL-METHYL) -2-THIOPHENE-CARBOXAMIDES AND USE THEREOF IN THE FIELD OF BLOOD COAGULATION | Bayer Pharma AG (DE) | 2011-10-05 | — | — | EP | disclosed |
| US-20100261759-A1 | SUBSTITUTED OXAZOLIDINONES AND THEIR USE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-10-14 | — | — | US | disclosed |
| US-20100261759-A1 | SUBSTITUTED OXAZOLIDINONES AND THEIR USE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-10-14 | — | — | US | disclosed |
| US-20100184740-A1 | SUBSTITUTED OXAZOLIDINONES AND THEIR USE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-07-22 | — | — | US | disclosed |
| US-20100184740-A1 | SUBSTITUTED OXAZOLIDINONES AND THEIR USE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140057951-A1 | SUBSTITUTED OXAZOLIDINONES AND THEIR USE | XDH, MPL, OXA1L | F2 30/4885F10 360/4885SMYD2 4566/4885 |
| US-20100184740-A1 | SUBSTITUTED OXAZOLIDINONES AND THEIR USE | XDH, MPL, OXA1L | F2 30/4885F10 360/4885SMYD2 4566/4885 |
| US-20100261759-A1 | SUBSTITUTED OXAZOLIDINONES AND THEIR USE | XDH, MPL, OXA1L | F2 30/4885F10 360/4885SMYD2 4566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.